These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37141665)

  • 21. Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
    Berruti A; Bitossi R; Bottini A; Bonardi S; Donadio M; Nigro C; Bertetto O; Danese S; Bertone E; Sarobba MG; Farris A; Katsaros D; Castiglione F; Volpe T; Lattuada S; Mancarella S; Dogliotti L
    Eur J Cancer; 2005 Jan; 41(2):249-55. PubMed ID: 15661550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
    Serin D; Verrill M; Jones A; Delozier T; Coleman R; Kreuser ED; Mross K; Longerey B; Brandely M
    Br J Cancer; 2005 Jun; 92(11):1989-96. PubMed ID: 15928659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
    Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
    Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy.
    Komen MMC; van den Hurk CJG; Nortier JWR; van der Ploeg T; Nieboer P; van der Hoeven JJM; Smorenburg CH
    Support Care Cancer; 2019 May; 27(5):1919-1925. PubMed ID: 30206728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.
    De Boer RH; Eisen TG; Ellis PA; Johnston SR; Walsh G; Ashley S; Smith IE
    Ann Oncol; 2002 Jun; 13(6):889-94. PubMed ID: 12123334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the Effects of Sesame Oil vs. Nitroglycerin Ointment on the Incidence of Chemotherapy-Induced Phlebitis: A Single Blind Clinical Trial.
    Safikani Mohammadzadeh N; Elahi N; Molavynejad S; Maraghi E; Ehsanpor A
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1113-1117. PubMed ID: 37116130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients.
    Fujii T; Ichiba K; Honda C; Tokuda S; Nakazawa Y; Ogino M; Kurozumi S; Obayashi S; Yajima R; Shirabe K
    Breast Cancer; 2021 Mar; 28(2):329-334. PubMed ID: 32944881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
    Basser RL; To LB; Collins JP; Begley CG; Keefe D; Cebon J; Bashford J; Durrant S; Szer J; Kotasek D; Juttner CA; Russell I; Maher DW; Olver I; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1999 Jan; 17(1):82-92. PubMed ID: 10458221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
    Kümmel S; Thomas A; Paepke S; Schwarz M; Heinrich G; Wetzel A; Elling D; Kohls A; Lichtenegger W; Blohmer JU
    Acta Oncol; 2005; 44(3):248-54. PubMed ID: 16076697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer.
    Tfayli A; Holter J; Bova A; Venkatappa S; Bullock S; Dooley W; Ozer H
    Anticancer Res; 2006; 26(6C):4911-6. PubMed ID: 17214361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
    Kouroussis C; Xydakis E; Potamianou A; Giannakakis T; Kakolyris S; Agelaki S; Sara E; Malamos N; Alexopoulos A; Mavroudis D; Samonis G; Papadouris S; Georgoulias V; Panagos G
    Ann Oncol; 1999 May; 10(5):547-52. PubMed ID: 10416004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
    Untch M; von Minckwitz G; Konecny GE; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Beckmann MW; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Nekljudova V; Lebeau A; Loibl S; Fasching PA;
    Ann Oncol; 2011 Sep; 22(9):1999-2006. PubMed ID: 21382868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.
    Appel JM; Zerahn B; Møller S; Christensen HM; Søgaard P; Ejlertsen B; Fogh-Andersen N; Jensen BV; Nielsen DL
    Acta Oncol; 2012 Nov; 51(8):1054-61. PubMed ID: 22909389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
    Gennari A; Salvadori B; Donati S; Bengala C; Orlandini C; Danesi R; Del Tacca M; Bruzzi P; Conte PF
    J Clin Oncol; 1999 Nov; 17(11):3596-602. PubMed ID: 10550159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
    Baldini E; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Carnino F; Gallo L; Giannessi P; Conte PF; Orlandini C; Bruzzi P
    Br J Cancer; 2004 Jul; 91(1):45-9. PubMed ID: 15173858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment.
    Gori S; Rulli A; Mosconi AM; Sidoni A; Colozza M; Crinò L
    Tumori; 2006; 92(4):364-5. PubMed ID: 17036534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.